Fundació Althaia
Welcome,         Profile    Billing    Logout  
 5 Trials 
14 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fernandez, Rafael
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
point, MFAR Sponsor designated contact
RADIAN, NCT05784012 / 2023-000183-65: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
1/2
34
Europe
Dostarlimab, Niraparib, cisplatin plus radiotherapy
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, GlaxoSmithKline, MFAR
Head and Neck Squamous Cell Carcinoma
09/27
03/29
Sponsor, A responsible person Designated by the
PROTINCOL, NCT05625932 / 2022-001534-11: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Recruiting
3
526
Europe
Tinzaparin, Innohep
Galician Research Group on Digestive Tumors, LEO Pharma
Colorectal Cancer Metastatic, Thromboembolism
12/24
03/25
SITISVEAL, NCT05542342 / 2021-002474-99: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

Completed
2
16
Europe
Tislelizumab, Sitravatinib Malate
Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene
Uveal Melanoma
12/23
05/25
NCT06538857: CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting
2
39
Europe
Standard surgery, CEB-01
CEBIOTEX, MFAR
Pancreatic Carcinoma
09/28
09/28
SETHY, NCT06235216: Sacituzumab govitEcan in THYroid Cancers

Recruiting
2
42
Europe
Sacituzumab govitecan, Trodelvy
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Gilead Sciences
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
12/27
12/27
VEXILLUM, NCT05219435 / 2021-005364-22: Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Recruiting
2
66
Europe
Nivolumab, Opdivo, Ipilimumab, Yervoy
Spanish Oncology Genito-Urinary Group, Bristol-Myers Squibb
Urothelial Cancer
03/25
12/25
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
CABOTHYROID, NCT05660954: Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting
2
41
Europe
Cabozantinib
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR
Differentiated Thyroid Cancer
06/25
06/25
PlugIN, NCT06906822: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Not yet recruiting
2
60
Europe
enfortumab vedotin, pembrolizumab
Grupo Español Multidisciplinar de Melanoma, Merck Sharp & Dohme LLC, Astellas Pharma Inc
Melanoma
06/27
06/28
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Active, not recruiting
1
21
Europe
CEB-01 membrane loaded with SN-38
CEBIOTEX
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
05/25
05/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fernandez, Rafael
NCT06384157: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Recruiting
2
300
US
INDV-2000, Placebo
Indivior Inc.
Opioid Use Disorder
08/25
09/25
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
point, MFAR Sponsor designated contact
RADIAN, NCT05784012 / 2023-000183-65: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
1/2
34
Europe
Dostarlimab, Niraparib, cisplatin plus radiotherapy
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, GlaxoSmithKline, MFAR
Head and Neck Squamous Cell Carcinoma
09/27
03/29
Sponsor, A responsible person Designated by the
PROTINCOL, NCT05625932 / 2022-001534-11: TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Recruiting
3
526
Europe
Tinzaparin, Innohep
Galician Research Group on Digestive Tumors, LEO Pharma
Colorectal Cancer Metastatic, Thromboembolism
12/24
03/25
SITISVEAL, NCT05542342 / 2021-002474-99: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.

Completed
2
16
Europe
Tislelizumab, Sitravatinib Malate
Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene
Uveal Melanoma
12/23
05/25
NCT06538857: CEB-01 in Locally Resectable Pancreatic Cancer

Recruiting
2
39
Europe
Standard surgery, CEB-01
CEBIOTEX, MFAR
Pancreatic Carcinoma
09/28
09/28
SETHY, NCT06235216: Sacituzumab govitEcan in THYroid Cancers

Recruiting
2
42
Europe
Sacituzumab govitecan, Trodelvy
Grupo Espanol de Tumores Neuroendocrinos, MFAR, Gilead Sciences
Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
12/27
12/27
VEXILLUM, NCT05219435 / 2021-005364-22: Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Recruiting
2
66
Europe
Nivolumab, Opdivo, Ipilimumab, Yervoy
Spanish Oncology Genito-Urinary Group, Bristol-Myers Squibb
Urothelial Cancer
03/25
12/25
ENCEFALO, NCT06887088: Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Recruiting
2
33
Europe
Encorafenib + Binimetinib, cemiplimab+fianlimab
Grupo Español Multidisciplinar de Melanoma, Regeneron Pharmaceuticals, MFAR, Pierre Fabre Laboratories
Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
01/28
01/28
CABOTHYROID, NCT05660954: Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting
2
41
Europe
Cabozantinib
Grupo Espanol de Tumores Neuroendocrinos, Ipsen, MFAR
Differentiated Thyroid Cancer
06/25
06/25
PlugIN, NCT06906822: PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

Not yet recruiting
2
60
Europe
enfortumab vedotin, pembrolizumab
Grupo Español Multidisciplinar de Melanoma, Merck Sharp & Dohme LLC, Astellas Pharma Inc
Melanoma
06/27
06/28
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
CAN-201 NDG, NCT05635734 / 2022-002801-36: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
18
Europe
Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
Cantex Pharmaceuticals, Cantex Pharmaceuticals Inc.
Glioblastoma
12/24
12/25
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Active, not recruiting
1
21
Europe
CEB-01 membrane loaded with SN-38
CEBIOTEX
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
05/25
05/25

Download Options